Patents by Inventor Murray B. UROWITZ

Murray B. UROWITZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20200338195
    Abstract: The present invention provides a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B comprising periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.
    Type: Application
    Filed: July 16, 2020
    Publication date: October 29, 2020
    Applicant: XTL BIOPHARMACEUTICALS LTD.
    Inventors: Murray B. UROWITZ, David ISENBERG, Daniel WALLACE, Monique BEN-AM, Joshua LEVINE, Daphna PARAN
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 0.5 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20180043017
    Abstract: Provided is a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B. The method may include periodic administration to the human subject of one subcutaneous injection of 0.5 mg dose of Edratide every week, so as to treat the human subject.
    Type: Application
    Filed: August 10, 2017
    Publication date: February 15, 2018
    Applicant: XTL Biopharmaceuticals Ltd.
    Inventors: Murray B. UROWITZ, David ISENBERG, Daniel WALLACE, Monique BEN-AM, Joshua LEVINE
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20180043016
    Abstract: Provided is a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B. The method may include periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.
    Type: Application
    Filed: August 10, 2017
    Publication date: February 15, 2018
    Applicant: XTL Biopharmaceuticals Ltd.
    Inventors: Murray B. UROWITZ, David ISENBERG, Daniel WALLACE, Monique BEN-AM, Joshua LEVINE, Daphan PARAN